MFS
BTAI icon

Mirabella Financial Services’s BioXcel Therapeutics BTAI Stock Holding History

Mirabella Financial Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,017
Closed -$349K – 410
2022
Q4 		$349K Buy
+1,017
New +$246K 0.03% 237

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Mirabella Financial Services's BTAI Position: Q1 2023 in Review

Mirabella Financial Services sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 1,017 shares — an estimated $349K sold.

Mirabella Financial Services first reported a position in BTAI in Q4 2022 and held it in 1 quarter. The position peaked at $349K in Q4 2022. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

  • Mirabella Financial Services reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mirabella Financial Services sold 1,017 BioXcel Therapeutics shares in Q1 2023, an estimated $349K.
  • Mirabella Financial Services first reported a position in BioXcel Therapeutics in Q4 2022 and held it in 1 quarter.
  • Mirabella Financial Services's BioXcel Therapeutics position peaked at $349K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on Mirabella Financial Services's 13F filing for Q1 2023, filed 12 May 2023.